Multicase is hosting a virtual event “Exploring the CPCA Framework: Defining Acceptable Intake for NDSRIs” on January 9 and 11 2024
Join us for a comprehensive analysis of the CPCA, which will examine the framework’s scope, background, and practical applications through the CPCA prediction module in QSAR Flex. Case studies highlighting the derivation of alternative acceptable intake (AI) limits via surrogates or leveraging other qualified safety data will be presented, offering a detailed look at the scientific rationale behind second tiered, non-CPCA predictions
Topics:
- Intro to CPCA Framework within QSAR Flex - Suman Chakravarti, MultiCASE
- Case studies using CPCA prediction module and surrogates with carcinogenicity data in QSAR Flex, including other considerations to offer a rational for alternative acceptable intake (AI) limits - Alejandra Trejo-Martin, Gilead Science
- Effect of surrogates with robust carcinogenicity data on establishing the acceptable intake limit for NDSRIs - Roustem Saiakhov, MultiCASE
Info and registration: https://register.gotowebinar.com/rt/7410594456597570648
